Compare Abbott Laboratories (ABT) vs Trip.com Group Ltd (TCOM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Trip.com Group Ltd — how do they compare? Abbott Laboratories trades at $95.15 (market cap $166.94B), while Trip.com Group Ltd trades at $41.51 (market cap $25.65B). The key difference: Abbott Laboratories is far larger — about 6.5× Trip.com Group Ltd's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | TCOM | |
|---|---|---|
Market Cap | $166.94B | $25.65B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $78.96 |
52-Week Low | $82.57 | $39.84 |
Enterprise Value | $193.69B | $18.35B |
Dividend Yield | 2.63% | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Trip.com Group (TCOM) trades at $40.81, down 0.46% on the day, near its 52-week low. The stock shows bearish technical signals with oversold RSI readings. Fundamentally, TCOM reported Q1 2026 revenue growth of 17% year-over-year but missed EPS estimates, with Q2 revenue guidance of 3%-8% growth disappointing investors. The company maintains strong profitability with a 48.65% net margin and attractive valuation multiples, including a P/E of 6.16. Recent news highlights regulatory scrutiny and a significant stock selloff following earnings.
The outlook for TCOM is mixed. Strong cash flow, dominant market position in Chinese travel, and low valuations support upside potential toward the $56.72 analyst target. However, near-term risks include regulatory investigations, margin pressure from cost growth, and bearish technical trends. Investors should weigh solid fundamentals against heightened sentiment risks and guidance concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →
